Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4518377
Max Phase: Preclinical
Molecular Formula: C83H121N13O29S
Molecular Weight: 1797.01
Molecule Type: Unknown
Associated Items:
ID: ALA4518377
Max Phase: Preclinical
Molecular Formula: C83H121N13O29S
Molecular Weight: 1797.01
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
Standard InChI: InChI=1S/C83H121N13O29S/c1-2-3-26-60(77(110)88-50-70(100)90-64(46-56-49-87-59-27-22-21-25-58(56)59)79(112)96-67(51-97)82(115)95-66(48-75(107)108)81(114)93-62(76(84)109)44-54-23-17-16-18-24-54)92-78(111)63(45-55-30-32-57(33-31-55)125-126(118,119)120)94-80(113)65(47-74(105)106)91-72(102)53-124-43-41-122-39-37-86-71(101)52-123-42-40-121-38-36-85-68(98)35-34-61(83(116)117)89-69(99)28-19-14-12-10-8-6-4-5-7-9-11-13-15-20-29-73(103)104/h16-18,21-25,27,30-33,49,60-67,87,97H,2-15,19-20,26,28-29,34-48,50-53H2,1H3,(H2,84,109)(H,85,98)(H,86,101)(H,88,110)(H,89,99)(H,90,100)(H,91,102)(H,92,111)(H,93,114)(H,94,113)(H,95,115)(H,96,112)(H,103,104)(H,105,106)(H,107,108)(H,116,117)(H,118,119,120)/t60-,61-,62-,63-,64-,65-,66-,67-/m0/s1
Standard InChI Key: KHGSCPBMZXNRNV-OMBHGISSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1797.01 | Molecular Weight (Monoisotopic): 1795.8114 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sensfuss U, Kruse T, Skyggebjerg RB, Uldam HK, Vestergaard B, Huus K, Vinther TN, Reinau ME, Schéele S, Clausen TR.. (2019) Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists., 62 (3): [PMID:30624060] [10.1021/acs.jmedchem.8b01558] |
Source(1):